Dow Turns Lower; Myomo Shares Jump
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- U.S. Stock Market: Dow Jones traded down 0.19%, NASDAQ rose 0.21%, and S&P 500 fell 0.02%.
- Top Headline: Eli Lilly to acquire Morphic Holding Inc for $3.2 billion.
- Equities Trading UP: MORF shares surged by 75%, MYO shares boosted by 27%, SVMH shares gained 39%.
- Equities Trading DOWN: HLVX shares dropped 87%, WETH shares down 20%, IVA shares fell 10%.
- Commodities: Oil and gold prices down, silver and copper also saw declines.
Analyst Views on MYO
Wall Street analysts forecast MYO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYO is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 10.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.949
Low
4.00
Averages
6.50
High
10.50
Current: 0.949
Low
4.00
Averages
6.50
High
10.50
About MYO
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
